MedTrace Logo

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

NCT01095224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-10-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immune response of an adenovirus-based HIV-1 vaccine regimen that includes two vaccines given at different time points in HIV-uninfected adults.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

rAd35 Env A

1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid

BIOLOGICAL

rAd5 Env A

1 x 10\^10 PU administered as 1 mL IM in deltoid

BIOLOGICAL

rAd5 Env B

1 x 10\^10 PU administered as 1 mL IM in deltoid

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Xia Jin, MD, PhD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-10-31
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095224 on ClinicalTrials.gov